Convalescent Coronavirus Disease 2019 Plasma Donor Profile: A Tertiary Care Hospital-based Study
Biomedical and Biotechnology Research Journal · 2023
DOI: 10.4103/bbrj.bbrj_102_23 ↗Abstract
Background: Currently, there is no specific treatment for coronavirus infections. Many trials are investigating the safety and efficacy of COVID-19 convalescent plasma (CCP) in critically ill coronavirus disease 2019 (COVID-19) patients. Case reports and case series have shown encouraging results. This retrospective study reports the Indian experience of CCP donor selection and donations. Methods: The donors aged 18-60 who had recovered from COVID-19 at least 28days before were recruited for COVID-19 convalescent plasma donation between August to December 2020. Results: During the period, 201 of 205 donors recruited were judged eligible and underwent plasmapheresis procedures. Ninety-nine percent (200/201) of the CCP donors were male. The average time between recovery from symptoms and CCP donation was 71.15 (±29.6) days. Two hundred and one plasmapheresis procedures were performed with an average volume of 494 (±34.0) ml of collected plasma, divided into two subunits (total 402). Ninety-two percent of CCP donors at the time of plasma donation had anti-severe acute respiratory syndrome coronavirus-2 IgG titer of >6. Plasmapheresis-related adverse reactions occurred in 1.46% (3/205) of cases; all reactions were mild, and none required therapeutic intervention. Changes in IgG titer against S-protein showed an upward trend and positively correlated with time from the onset of disease symptoms to the plasma donation. Conclusion: This study demonstrates the feasibility and safety of a CCP donation program. Identifying factors positively associated with higher antibody titers at the time of donation may help optimize the selection of CCP donors.
EUVIMED